DBV Technologies (DBVT) Operating Income (2020 - 2026)
DBV Technologies (DBVT) posted Operating Income of -$50.6 million for Q2 2026, down 5.64% sequentially from -$47.9 million in Q1 2026, and down 23.11% YoY from -$65.8 million in Q2 2025.
DBV Technologies (DBVT) Operating Income (2020 - 2026) Analysis & Trends
DBV Technologies has reported Operating Income for 7 years, with the latest figure at -$50.6 million in Q2 2026.
- Quarterly Operating Income fell 23.11% year-over-year to -$50.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$177.8 million (down 45.89% YoY) and the FY2025 annual result came in at -$147.1 million, down 26.13% from the prior year.
- Operating Income slipped to -$50.6 million in Q2 2026 per DBVT's latest filing, from -$47.9 million in the prior quarter.
- Over five years, Operating Income peaked at -$11.9 million in Q4 2023 and troughed at -$50.6 million in Q2 2026.
- A 5-year average of -$29.7 million and a median of -$27.6 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2023: Operating Income slumped 182.09% in 2022, then soared 68.65% in 2023.
- Over 5 years, Operating Income stood at -$38.0 million in 2022, then surged by 68.65% to -$11.9 million in 2023, then plunged by 100.18% to -$23.9 million in 2024, then slumped by 88.81% to -$45.1 million in 2025, then declined by 12.32% to -$50.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$50.6 million, -$47.9 million, and -$45.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | -50.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -50.60 Mn |
| Mar 31, 2026 | -47.90 Mn |
| Dec 31, 2025 | -45.05 Mn |
| Sep 30, 2025 | -34.28 Mn |
| Jun 30, 2025 | -41.10 Mn |
| Mar 31, 2025 | -26.60 Mn |
| Dec 31, 2024 | -23.86 Mn |
| Sep 30, 2024 | -30.33 Mn |
| Jun 30, 2024 | -33.84 Mn |
| Mar 31, 2024 | -28.56 Mn |
| Dec 31, 2023 | -11.92 Mn |
| Sep 30, 2023 | -18.27 Mn |
| Jun 30, 2023 | -25.08 Mn |
| Mar 31, 2023 | -21.17 Mn |
| Dec 31, 2022 | -38.02 Mn |
| Sep 30, 2022 | -18.02 Mn |
| Jun 30, 2022 | -23.82 Mn |
| Mar 31, 2022 | -16.77 Mn |
| Dec 31, 2021 | -13.48 Mn |
| Sep 30, 2021 | -24.37 Mn |